CRP and myocardial infarction: In another approach, pharmacological inhibition of CRP using a PCh-based compound reduced the deposition of CRP at myocardial infarcts and inhibited complement activation, indicating that the PCh-binding site of CRP participates in worsening the infarct size and that the inhibition of the PCh-binding site is a useful strategy to prevent tissue-damaging conditions [38].